Curet Myriam

ISRG Chief Medical Officer sells 4,853 shares (92.2% of holdings) across 2 transactions for $2,364,960.79

Myriam Curet, EVP & Chief Medical Officer, executed 2 separate sales totaling 4,853 shares for $2,364,960.79, reducing her holdings from 5,262 shares to 409 shares (92.2% reduction). Her same-ticker sales history shows a strong pattern: 4 of 4 prior sells at ISRG were well-timed at the 90-day mark, with negative 90-day returns after the sales. However, the cross-ticker track record shows her sells average +1.4% 30-day return and +3.0% 90-day return with a 47.06% well-timed rate, indicating mixed timing ability across other stocks. The stock currently trades at $497.42, down 1.4% over 30 days and down 12.7% over 90 days, and is down 16.1% from its 52-week high of $592.85. The company shows robust fundamentals: $2,505,100,000 quarterly revenue with 20.5% annual growth and $704,400,000 net income, though the P/E of 53.83 reflects a premium valuation. The scale of this sale—reducing her stake to 409 shares—merits attention given her C-suite medical leadership role, though the transaction does not definitively signal material adverse information absent additional context.

Director Curet nets 1-share sale across 4 transactions (mixed buys and sells); currently $117.29 vs 52-week high of $215.42.

Curet Myriam executed 4 separate transactions over five months: 2 purchases totaling 5 shares for $803.62 and 2 sales totaling 6 shares for $615.55, resulting in a net 1-share sale. The buying occurred at $163.84 and $148.26 (March and April), while the selling occurred at much lower prices of $153.22 and $77.28 (May and August). This price progression—with the August sale at $77.28 representing a 53% decline from the March purchase price of $163.84—suggests the director was selling at depressed valuations. Currently at $117.29, the stock has recovered from the August lows but remains 45.6% below its 52-week high of $215.42. The director's post-transaction holdings of 3,365 shares represent minimal portfolio impact (net change of -1 share), making this a marginal activity that does not materially alter her director-level position.

CMO Myriam Curet liquidates entire 7,687-share position in 4 sales totaling $4.2M at $548.34 avg on Oct 28-29

Myriam Curet, EVP & Chief Medical Officer of Intuitive Surgical, executed 4 separate sales totaling 7,687 shares for $4,215,067.88, liquidating her complete shareholding at a blended average price of $548.34. This represents a 100% exit from her position on Oct 28-29, 2025. In context of her cross-ticker trading history, her 18 prior sells show a well-timed rate of 23.53% (average 90-day return +6.9%), while her same-ticker ISRG history presents mixed timing: of 5 prior sells, 3 demonstrated negative 90-day returns (well-timed at those sales), though her most recent ISRG sale on 2025-07-25 saw the stock rise +11.9% over 90 days. The full liquidation at the company's current trading level ($537.59 today, +22.4% over 30 days) occurs against ISRG's strong fundamental backdrop: $2.5B quarterly revenue, +17.2% annual growth, and $704.4M net income, though the company trades at a 69.37 P/E multiple.

Chief Medical Officer Curet Myriam sold 4,500 shares of ISRG for $2.2M, reducing holdings by 92.7% to 353 shares.

Curet Myriam, EVP & Chief Medical Officer, executed a substantial sale of 4,500 shares at $492.48 on 2025-07-25, reducing her post-transaction holdings to 353 shares—a 92.7% reduction from pre-transaction holdings. This near-complete liquidation is notable given her senior role overseeing medical strategy at a $177.8B company with $2.4B quarterly revenue and 17.2% annual revenue growth. Her cross-ticker sell history shows a 17.65% well-timed rate (sells typically followed by declines), and 3 of her 5 prior ISRG-specific sells were well-timed at the 90-day mark, suggesting a pattern of selling ahead of downward moves. The stock has fallen 4.9% in the 30 days and 3.6% in 90 days since the transaction, and is currently trading 18.8% below its 52-week high at $495.86, which is consistent with her prior timing patterns at this ticker.

EVP & Chief Medical Officer Curet sold 4,000 shares of ISRG for $2.1M on 2025-04-25, reducing holdings by 91.9%.

Myriam Curet, EVP & Chief Medical Officer, sold 4,000 shares at $513.18, leaving her with only 353 shares post-transaction—a 91.9% reduction in her ISRG holdings. Her cross-ticker track record shows 18 prior sells with an average 90-day return of +15.2% and a 90d well-timed rate of 0.00%, indicating her recent sales have not preceded declines. At the same ticker, her three most recent prior sales in late 2024 and early 2025 show mixed outcomes: three November 2024 sales yielded +11.2% 90d returns, while two February-March 2025 sales have shown negative 30d returns (-15.4% and -12.2% respectively). The stock currently trades at $514.01, near the transaction price, within its 52-week range but -15.8% from the 52-week high. With ISRG's elevated P/E of 74.39 and strong but slowing recent momentum (30-day +4.5% but 90-day -10.5%), this substantial reduction by a senior medical executive warrants monitoring of company fundamentals and insider transaction flow.

EVP & Chief Medical Officer sold 3,031 shares (89.6% of holdings) at $577.30, retaining only 353 shares post-transaction.

Curet Myriam, EVP & Chief Medical Officer, sold 3,031 shares at $577.30 on 2025-03-03, reducing her position by 89.6% to just 353 shares remaining. This represents a substantial divestment of her stake in INTUITIVE SURGICAL, executed at a price $10.32 above the current $566.98 level. Among her prior 4 measurable sales at ISRG, none were well-timed against the 90-day benchmark—the stock rose an average of 11.2% post-sale in her last cluster of November 2024 transactions. Against her cross-ticker track record of 18 prior sales, her timing has been poor with a 0.00% well-timed rate and average 90-day return of +15.3%, indicating she tends to sell before the stock rallies. The near-elimination of her holdings signals a material reduction in personal investment conviction at current valuations, though the company's $2.0B quarterly revenue and 17.2% annual growth suggest operational strength.

Chief Medical Officer sold 2,401 shares (87.2% of holdings) at $581.00; 0 of 5 prior ISRG sales were well-timed at 90 days.

Myriam Curet, EVP & Chief Medical Officer, sold 2,401 shares representing 87.2% of her pre-transaction holdings, leaving just 353 shares. The sale occurred at $581.00, now 3.0% above the current price of $563.77. Across her 5 prior sales at ISRG, none were well-timed at the 90-day mark—her pattern shows average 90-day returns of +11.2% after most recent sales, indicating the stock typically appreciated after she sold. Her broader cross-ticker track record reflects similar outcomes: 17 prior sales with a 90-day well-timed rate of 0.00%, despite average 90-day returns of +15.3%, further suggesting systematic poorly-timed selling patterns. The near-complete liquidation of her ISRG position warrants examination of whether this reflects portfolio shifts or personal liquidity needs rather than a conviction signal about the company's outlook.

EVP & CMO Myriam Curet sold 13,466 shares of ISRG for $7.2M (97.8% of holdings) on 2024-11-12

Myriam Curet, EVP & Chief Medical Officer, executed 4 separate sales totaling 13,466 shares for $7,217,195.61 at $535.96 per share, reducing her holdings from 13,764 to 298 shares—a 97.8% reduction. The stock is trading at $536.69, near its 52-week high of $537.07, and has climbed 10.1% over 30 days and 11.8% over 90 days. Across her prior trades at ISRG (5 total), none were well-timed at the 90-day mark, with those sales followed by positive returns averaging 10.1% over 90 days—indicating the insider's recent historical sells at this ticker preceded further gains. The near-complete liquidation by a senior medical executive at peak price levels warrants attention to the underlying circumstances, though the multi-transaction structure and the stock's strong recent momentum provide context for investor evaluation.

ISRG CMO Curet sells 2,818 shares (90.4% of holdings) for $1.3M at $458.13; stock flat to prior highs, insider's 5 prior ISRG sells all posted positive 90d returns

Myriam Curet, EVP & Chief Medical Officer, executed a substantial sale of 2,818 shares ($1,291,010.34) on 2024-07-23, reducing her ISRG position from 3,116 to 298 shares, a -90.4% reduction. The transaction occurred near the 52-week high ($458.13 vs $461.12 peak); the stock has since moved sideways (−1.5% from 52-week high, +5.8% over 30 days). Examining her ticker-specific history reveals a consistent pattern: all 5 of Curet's prior ISRG sales (Jan, Mar, Apr, Apr 2024) posted positive 90-day returns (+0.8% to +24.4%), indicating that in this insider's history at ISRG, sell timing has failed to precede downturns. The latest sale occurred at an elevated price relative to recent volatility and follows the same pattern—a sales signal where the historical outcome has been stock appreciation rather than decline. This concentration of selling activity from a chief medical officer warrants monitoring for any connection to operational or strategic developments.